Vimal D. Mehta Ph.D.
Net Worth

Last updated:

What is Vimal D. Mehta Ph.D. net worth?

The estimated net worth of Dr. Vimal D. Mehta Ph.D. is at least $29,291,070 as of 16 Dec 2024. He owns shares worth $303,342 as insider, has earned $18,837,728 from insider trading and has received compensation worth at least $10,150,000 in BioXcel Therapeutics, Inc..

What is the salary of Vimal D. Mehta Ph.D.?

Dr. Vimal D. Mehta Ph.D. salary is $1,450,000 per year as Founder, Chief Executive Officer, Pres, & Director in BioXcel Therapeutics, Inc..

How old is Vimal D. Mehta Ph.D.?

Dr. Vimal D. Mehta Ph.D. is 64 years old, born in 1961.

What stocks does Vimal D. Mehta Ph.D. currently own?

As insider, Dr. Vimal D. Mehta Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
BioXcel Therapeutics, Inc. (BTAI) Founder, Chief Executive Officer, Pres, & Director 59,605 $5.09 $303,342

What does BioXcel Therapeutics, Inc. do?

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI logo
BTAI
BioXcel Therapeutics, Inc.
$5.09

Vimal D. Mehta Ph.D. insider trading

BioXcel Therapeutics, Inc.

Dr. Vimal D. Mehta Ph.D. has made 30 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,134 units of BTAI stock worth $773 on 16 Dec 2024.

The largest trade he's ever made was exercising 609,221 units of BTAI stock on 4 Jun 2024. As of 16 Dec 2024 he still owns at least 59,605 units of BTAI stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,134 $0.36 $773
Sale
Common Stock 983 $0.36 $358
Option
Common Stock 3,500 N/A N/A
Option
Restricted Stock Units 3,500 N/A N/A
Option
Restricted Stock Units 2,610 N/A N/A
Option
Common Stock 2,610 N/A N/A
Sale
Common Stock 832 $0.69 $573
Sale
Common Stock 1,150 $0.69 $795
Option
Common Stock 3,500 N/A N/A
Option
Restricted Stock Units 3,500 N/A N/A
Option
Restricted Stock Units 2,609 N/A N/A
Option
Common Stock 2,609 N/A N/A
Sale
Common Stock 2,134 $1.28 $2,740
Option
Common Stock 3,500 N/A N/A
Option
Restricted Stock Units 3,500 N/A N/A
Option
Restricted Stock Units 2,609 N/A N/A
Option
Common Stock 2,609 N/A N/A
Sale
Common Stock 283,122 N/A N/A
Sale
Common Stock 126,014 $1.58 $199,606
Sale
Call Options (obligation to sell) 120 N/A N/A
Sale
Common Stock 609,221 N/A N/A
Sale
Common Stock 126,014 $1.63 $205,529
Sale
Common Stock 283,123 N/A N/A
Sale
Common Stock 829 $2.62 $2,172
Sale
Common Stock 4,439 $2.63 $11,652
Option
Common Stock 14,000 N/A N/A
Option
Restricted Stock Units 14,000 N/A N/A
Option
Restricted Stock Units 2,610 N/A N/A
Option
Common Stock 2,610 N/A N/A
Option
Common Stock 2,609 N/A N/A
Option
Restricted Stock Units 2,609 N/A N/A
Option
Restricted Stock Units 2,610 N/A N/A
Option
Common Stock 2,610 N/A N/A
Sale
Common Stock 24,987 $20.01 $499,990
Sale
Common Stock 4,266 $20.9 $89,159
Option
Common Stock 30,000 $0.41 $12,300
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Sale
Common Stock 747 $21.89 $16,352
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Sale
Common Stock 21,988 $21.41 $470,763
Sale
Common Stock 8,012 $21.9 $175,463
Option
Restricted Stock Units 2,609 N/A N/A
Option
Common Stock 2,609 N/A N/A
Sale
Common Stock 6,500 $25.79 $167,642
Option
Restricted Stock Units 15,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Sale
Common Stock 900 $20.15 $18,135
Option
Common Stock 30,000 $0.41 $12,300
Sale
Common Stock 29,100 $19.7 $573,270
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Sale
Common Stock 604 $18.88 $11,404
Sale
Common Stock 3,896 $18.22 $70,985
Sale
Common Stock 5,333 $18.86 $100,580
Sale
Common Stock 24,667 $18.2 $448,939
Option
Common Stock 30,000 $0.41 $12,300
Option
Common Stock 10,437 N/A N/A
Option
Restricted Stock Units 10,437 N/A N/A
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Option
Common Stock 30,000 $0.41 $12,300
Sale
Common Stock 9,887 $19.92 $196,949
Sale
Common Stock 20,113 $19.21 $386,371
Option
Stock Option (Right to Buy) 30,000 $0.41 $12,300
Sale
Common Stock 7,206 $20.19 $145,489
Option
Common Stock 30,000 $0.41 $12,300
Sale
Common Stock 22,794 $19.86 $452,689
Sale
Common Stock 473,250 $30.83 $14,589,351
Purchase
Common Stock 974 N/A N/A
Purchase
Common Stock 2,625 $8.67 $22,759
Purchase
Common Stock 358 $8.44 $3,022
Purchase
Common Stock 1,000 $8.75 $8,750
Purchase
Common Stock 2,000 $4.41 $8,824
Purchase
Common Stock 1,000 $5.15 $5,150
Purchase
Common Stock 1,000 $5.17 $5,168
Purchase
Common Stock 1,000 $5.19 $5,193

BioXcel Therapeutics key executives

BioXcel Therapeutics, Inc. executives and other stock owners filed with the SEC: